Kornimate/medical-research-clean huggingface dataset:
evaluation of the coping long term with active suicide program

Conditions: Suicide

Summary: the purpose of this study is to evaluate the utility of the coping long term with active suicide program (clasp) for reducing suicidal behavior.


Eligibility criteria:
inclusion criteria: 1. current patient at butler hospital 2. suicide attempt or suicidal ideation with intent to make a suicide attempt within 48 hours of hospitalization as indicated on the hospital chart and confirmed by administration of the c-ssrs 3. age \> 18 years 4. have a reliable telephone 5. ability to speak, read, and understand english well to complete the procedures of the study exclusion criteria: 1. current psychotic symptoms severe enough to impair study participation 2. participation in a treatment program with established efficacy in preventing suicidal behavior 3. cognitive impairment which would interfere with adequate participation in the project (mmse\< 20). 4. currently in state custody or pending legal action 5. already enrolled current or previous clasp trial
individually tailored and integrated social support network for tobacco cessation

Conditions: Smoking Cessation

Summary: this study will continue development of a quit smoking program delivered through text messaging. upon completion of programming we will enroll 280 participants and randomize them to a control condition or the intervention condition. assessments will occur at enrollment, and both 3 and 6 month follow ups.

this study builds on pilot work in which live inspired llc and research partners developed t2q (formerly "text-2-quit") a smoking cessation intervention delivered through text messaging. t2q is a unique program with a number of features that provide superior support and service compared to existing text message quit smoking products. t2q is 100% accessible through text messaging provides medication support for quitting smoking, an integrated social support network and live counseling. this phase ii project will add functionality to accommodate use of multiple forms of quit smoking medications, and then conduct a rigorous test of the efficacy of t2q among 280 adult smokers and examine smoking outcomes compared to controls at 3 and 6 months follow up. the study will also examine changes in smoking-related attitudes and behaviors among t2q users to identify strengths and any potential weaknesses that may affect t2q's impact on smoking outcomes. analyses will examine the quality of social interactions within the t2q integrated social support network and their role in promoting smoking abstinence. we will also conduct interviews with study participants in the t2q arm to enable understanding of the user's experience with t2q. results of this trial will demonstrate the efficacy of t2q - providing important credibility needed for successful commercialization. this research will also provide important data for possible enhancements to improve consumer appeal prior to commercialization. this proposal finalizes development and testing of a unique, highly scalable intervention that can reach a u.s. market comprised of over 34 million adult smokers who use text messaging, and provide them with effective, evidence-based treatment. text messaging enjoys near-market saturation and is a widely preferred method of communication with deep penetration across diverse groups. wide availability of an attractive and effective smoking cessation program such as t2q, may exert a powerful, sustained impact on public health

Eligibility criteria:
inclusion criteria: * age \>18 * current daily cigarette smoker * use of text messaging at least once per week * interested in quitting smoking within the next 30 days * has access to a physician or healthcare provider * no current drug/alcohol abuse. exclusion criteria: * non-english speaking * currently using quit-smoking medications or therapies

Keywords: tobacco, smoking, text message
efficacy of intrathecal administration of liposomal amphotericin b in cryptococcal meningitis

Conditions: Cryptococcal Meningitis

Summary: the main purpose of this study is to observe the clinical effect of intrathecal administration of liposomal amphotericin b in cryptococcal meningitis without acquired immune deficiency syndrome (aids).


Eligibility criteria:
inclusion criteria: * cryptococcus neoformans are found in csf exclusion criteria: * patients with serious heart, lung, liver and renal insufficiency. * patients who took broad-spectrum antibiotics and corticosteroids for a long-term. * patients with aids or obvious immunodeficiency. * patients with long term dialysis or intravenous catheter. * patients with other brain organic disease such as purulent meningitis, intracranial swelling, etc.

Keywords: intrathecal administration liposomal amphotericin b without acquired immune deficiency syndrome
the support, educate, empower (see) program

Conditions: Glaucoma

Summary: this study will test whether the support, educate, empower (see) personalized glaucoma coaching program improves eye drop medication adherence among glaucoma patients compared to enhanced standard care in a randomized controlled clinical trial. as a secondary outcome, the study will test whether glaucoma related distress decreases among see program participants compared to the control group. the study hypothesis is that glaucoma patients with poor adherence who receive motivational-interviewing based counseling and personalized education from a trained non-physician glaucoma coach through the see program will improve their medication adherence compared to glaucoma patients standard care enhanced by additional educational handouts.


Eligibility criteria:
inclusion criteria: * taking greater or equal to 1 ocular hypotensive medication with a diagnosis of any kind of glaucoma, suspected glaucoma or ocular hypertension * did not opt-out from recruitment letter exclusion criteria: * do not speak english * have a diagnosed serious mental illness (for example, schizophrenia) * diagnosed cognitive impairment * do not instill their own eye drops * had laser or incisional glaucoma surgery within three months of enrollment or scheduled during the six-month study period * unable to attend all study visits * active ocular infection or uveitis

Keywords: ophthalmology glaucoma medication adherence motivational interviewing tailored education self management
the impact on ovarian reserve after single-port, two-port, or four-port access laparoscopic ovarian cyst enucleation

Conditions: Ovarian Cyst

Summary: the purpose of this study is to investigate the impact on ovarian reserve after single- port, two-port, or four-port access laparoscopic ovarian cyst enucleation based on serum anti mullerian hormone change.

with the recent development of surgical instruments techniques, minimally invasive surgery is more feasible in various field of surgery. laparoscopic surgery has potential benefit of decreased patient discomfort, short hospital stay, superior cosmetic results and decreased convalescence time. recently, various efforts have been continued for minimally invasive surgery, one of the recently emerging concepts is single port surgery. several studies have demonstrated that single-port laparoscopic surgery is feasible and safe in gynecology. however, some limits could be occurred, such as the occurrence of less freedom degrees between the instruments and limits surgical vision, thus limiting surgeon's movements. so, two-port laparoscopy combined access through umbilical and additional suprapubic incision have been used and reported. in case of single port access laparoscopic ovarian cyst enucleation, due to limits of surgeon's movements, cyst enucleation or bipolar electrocoagulation of the ovarian parenchyma adversely affected ovarian function. some studies reported that after laparoscopic cyst enucleation, there had been shown marked reduction of ovarian function compared with surgery by laparotomy. therefore we attempt to investigate the impact of single port laparoscopy that have limits of surgical procedures on ovarian reserve after ovarian cyst enucleation. to evaluate ovarian reserve change, we will use the anti-mullerian hormone. it is produced by granulosa cells of preantral and small antral follicles and has been recently acknowledged as the useful, reliable, and sensitive hormonal serum marker of the ovarian primordial follicle pool. in addition, the amh level represents a stronger independent marker of ovarian reserve without significant fluctuation during the menstrual cycle, which progressively decreases with age. therefore, this prospective study is performed to compare the differences in ovarian reserve after single-port, two-port, or four-port access laparoscopic ovarian cyst enucleation based on serum anti mullerian hormone change. serum anti mullerian hormone is measured at preoperative and at postoperative 1week, 1 and 3 months.

Eligibility criteria:
inclusion criteria: * age: 21-45 years ultrasound * ct, mri diagnosis as ovarian cyst , need to cyst enucleation * size of cyst : between 3cm and 10cm * regular menstrual cycles defined as cycle length between 25 and 35 days * agreement to be enrolled in the study. exclusion criteria: * previous ovarian surgery * suspicious of malignancy * postmenopause * use of oral contraceptive drug, gnrh agonist /antagonist, or other drugs related with ovarian function in last 3 months * known endocrine disorder
a study to investigate markers of inflammation in rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Osteoarthritis

Summary: this study is being conducted to validate various biomarkers in patients with ra with varying levels of disease severity. subjects with a diagnosis of rheumatoid arthritis (ra) will be included as controls. the sudy will measure the baseline levels and the intra- and inter-subject variability of exhaled nitric oxide (no) in patients with inactive/mild and moderate/severe ra on stable therapy or during a course glucocorticoids. in addition exhaled no levels will be correlated with intra-articular inflammation (power doppler ultrasonography) as well as markers of systemic inflammation (crp, esr).


Eligibility criteria:
inclusion criteria: * diagnosis of rheumatoid or osteo-arthritis. * weight greater than 45kg (females) or 50kg (males) but not overweight. * non-smokers. * taking stable anti-inflammatory medication for rheumatoid arthritis (ra) or osteoarthritis (oa) for at least 8 weeks. exclusion criteria: * taking regular doses of glucocorticoid medication (greater than 5mg/day). * currently taking biological treatment for ra. * recent participation in another clinical trial.

Keywords: inos rheumatoid arthritis exhaled no
bioelectrical impedance vector analysis in cirrhotic patients

Conditions: Cirrhosis; Hepatic Encephalopathy

Summary: protein-energy malnutrition and muscle wasting are a common finding among patients with liver cirrhosis. its prevalence may range from 50-90% depending on the methods used for nutritional assessment. even stable cirrhotic patients referred as child a have muscle depletion and the majority of patients classified as child c have significant depletion. malnutrition has been shown to be related to several complications of cirrhosis despite the importance of nutritional status in patient's outcome, there is no gold standard for nutritional assessment. traditional techniques used in healthy subjects to assess nutritional status cannot be used in cirrhotic patients due especially to ascites and peripheral edema, and altered rates of biochemical markers due to liver failure. bioelectrical impedance vector analysis has emerged as a useful method to assess body composition and nutritional status especially in patients at the extremes of body weight (fluid overload, excess of adipose tissue, etc.). the aim of this study is to evaluate whether malnutrition assessed by bioelectrical impedance vector analysis is related to the development of hepatic encephalopathy


Eligibility criteria:
inclusion criteria: * diagnose of cirrhosis. * ambulatory patients exclusion criteria: * personal history of surgery in the last four weeks * thyroid disorders without replacement therapy * pregnancy * active alcoholism with alcohol ingest in the previous 6 months. * acute or chronic renal failure * hepatic or renal transplant
a study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of hrs-1301 in healthy subjects

Conditions: Hyperlipidemia

Summary: this study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of hrs-1301 following single and multiple dose administration in healthy subjects. the study consists of two parts (part 1 and part 2) with 82 subjects planned to be enrolled. possible adjustments to sample size, treatment duration and follow-up time will depend upon emerging data.


Eligibility criteria:
inclusion criteria: 1. healthy male and female subjects must be at least 18 years old and no more than 55 years old on the date of signing the icf. 2. the female subjects must be non-pregnant or non-childbearing potential. 3. subjects must understand the study procedures and methods, voluntarily participate in this study and sign the icf in person. exclusion criteria: 1. have a gastrointestinal, liver or kidney disease or other condition known to affect drug absorption, distribution, metabolism and excretion or to reduce adherence, as determined by the investigator. 2. those who had severe trauma or had undergone surgery within 3 months prior to screening, or planned to undergo surgery during the trial. 3. have a history of repeated drug allergies. 4. people who have used any drug in the 2 weeks prior to screening. 5. those who received live (attenuated) vaccine within 4 weeks prior to screening or planned to receive it during the trial.
evaluation of svv from nicom as a predictor of fluid responsiveness in prone position during spine surgery

Conditions: Fluid Responsiveness; Prone Position; Non Invasive Cardiac Output Monitoring

Summary: nicom® is a recently developed noninvasive cardiac output monitoring device, and indices derived from nicom® such as svv has been reported to predict fluid responsiveness in the previous studies. however, its usefulness in prone positioning has not been investigated. thus, the aim of this prospective observational study is to evaluate the usefulness of stroke volume variation (svv) derived from nicom® to predict fluid responsiveness in prone patients undergoing spine surgery.


Eligibility criteria:
inclusion criteria: * asa i or ii patients undergoing spine surgery in prone position exclusion criteria: * pre-existing arrhythmic disorders/moderate to severe valvular heart disease/obstructive pulmonary disease (copd grade \>2), left ventricular dysfunction with lv ef less than 50, preoperative need for inotropics or vasopressors * bmi \>30kg/m\^2 or \<15kg/m\^2 * preoperative serum cr \> 1.3mg/dl * patients with coagulopathy

Keywords: fluid responsiveness nicom prone position stroke volume variation
a study of mk0653a (ezetimibe (+) simvastatin) in patients with hypercholesterolemia (0653a-038)

Conditions: Hypercholesterolemia

Summary: the purpose of this study is to evaluate the lipid lowering effects of an investigational drug in patients with hypercholesterolemia (high cholesterol).

the duration of treatment is 4 months.

Eligibility criteria:
inclusion criteria: * high cholesterol exclusion criteria: * patient has a condition which, in the opinion of the investigator, might pose a risk to the patient, interfere with participation in the study, or does not meet the additional criteria as required by the study.

Keywords: primary hypercholesterolemia
prospective analysis to detect myometrial cells in peritoneal washing in patients undergoing minimally invasive hysterectomy using containment bag at university of texas medical branch

Conditions: Hysterectomy

Summary: the aim of the study is to determine endometrial/myometrial spillage during total laparoscopic hysterectomy with manual morcellation.

this will be a single institution prospective analysis study. the study will include 50 women who are undergoing minimally invasive hysterectomy. surgery will be done from 08/01/2023 to 08/01/2024, for benign conditions with uterus that is \> 10 cm that requires contained bag morcellation such as (fibroids, adenomyosis, endometriosis, abnormal uterine bleeding, pelvic organ prolapse). three samples of peritoneal washings will be collected and send to pathology. first washing will be collected after entering the abdominal cavity, second washing will be done after completion of hysterectomy and containment of the uterus in the bag, and the third washing after scalpel morcellation of the uterus in the containment bag and extraction within the bag. extraction of the specimen will be done either through the vagina or through a mini laparotomy incision (2-3 cm).

Eligibility criteria:
inclusion criteria: 1. women undergoing minimally invasive laparoscopic / robotic hysterectomy for presumably benign conditions such as (fibroids, adenomyosis, endometriosis, pelvic organ prolapse, abnormal uterine bleeding) 2. large size uterus measuring more than 10 cm on us requiring cold knife morcellation within the alexis containment bag, surgery will be done by designated surgeon at utmb from 08/01/2023 to 08/01/2024. 3. women 18 years and older 4. subjects must be able to provide consents. 5. normal endometrial biopsy. 6. normal cervical cancer screening exclusion criteria: 1. known gynecological malignancy. 2. endometrial biopsy with endometrial intraepithelial hyperplasia. 3. history of exposure to pelvic radiation 4. post-menopausal patients 5. emergency hysterectomy 6. tdc patients 7. patient less than 18 years old

Keywords: hysterectomy pelvic washings myometrial cell spillage fibroids
effect of biphasic insulin compared to biphasic insulin combined with insulin aspart, with or without metformin in type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in africa and middle east. the objective of the study is to compare glycemic control of biphasic insulin aspart 30 twice daily with biphasic insulin aspart 30 twice daily plus insulin aspart, both insulin treatments with or without metformin, in subjects with type 2 diabetes, previously treated with biphasic human insulin 30/70.


Eligibility criteria:
inclusion criteria: * type 2 diabetic subjects * current treatment with biphasic human insulin 30/70 twice daily alone or in combination with any oral hypoglycaemic agent for at least 3 months prior to entering the trial * hba1c at least 12% * willing and able to perform self blood glucose monitoring (smbg) exclusion criteria: * history of drug or alcohol dependence * receipt of any investigational drug within the last month prior to this trial * anticipated change in dose of prescription medication, which may influence glucose regulation (mono amino oxidase-inhibitors, non selective beta-adrenergic agents, anabolic steroids and systemic glucocorticoids) * severe uncontrolled hypertension * recurrent severe hypoglycemia as judged by investigator * any disease or condition, which the investigator feels, would interfere with the trial
different regimen of aprotinine(trasylol) administration in patients receiving antiplatelet therapy with clopidogrel (plavix)

Conditions: Coronary Artery Disease

Summary: clopidogrel (plavix), a platelet adp receptor antagonist, has become the standard of care to prevent thrombosis in interventional cardiology and is increasingly being used in unstable angina and nstemi. an increasing number of patients are referred to emergent or urgent cabg, and several studies, as well as our own experience, have shown that preoperative administration of irreversible platelets inhibitors increase the risk of bleeding complications following cabg.

aprotinine (trasylol) is a potent antifibrinolytic agent known to reduce bleeding after cardiac surgery. the most commeon practice is to give trasylol in high doses immediately before surgery, during the operation, and during the first postoperative hours. however, it has also been shown that there is a hemostatic effect of the drug when given in a lower dose postoperatively, but this remains unclear.

Eligibility criteria:
all coronary bypass operations in patients receiving plavix within the last 7 days
association of plasma metabolomic biomarkers with chronic ischemic white matter injury

Conditions: Myelinopathy

Summary: the cases were screened according to the inclusion criteria, and after the patients signed the informed consent, the clinical data were collected, the imaging data were evaluated, and blood samples were taken for follow-up measurements. in the early morning of the second day after the patient was enrolled, 5ml of peripheral venous blood was drawn and sent to the neurology laboratory of our hospital for separation, and the detection of plasma metabolomics markers was performed.

in the early morning of the second day after the patient was enrolled, 5ml of peripheral venous blood was drawn and sent to the neurology laboratory of our hospital for separation, and the detection of plasma metabolomics markers was performed.inluding crp，complete blood count，liver and kidney function indicators，et.

Eligibility criteria:
inclusion criteria： 1. be older than 45 years old; 2. patients admitted to the department of neurology due to headache, vertigo, anxiety, etc.; 3. there were no symptoms of neurological deficit on physical examination; 4. able to cooperate with the improvement of brain mri examination; 5. sign the informed consent form. exclusion criteria: 1. history of stroke, traumatic brain injury, intracranial tumor, central nervous system infection, active malignant tumor, thyroid disease, autoimmune disease, active or chronic inflammatory disease, severe liver and kidney impairment, etc.; 2. accompanied by neurological deficit symptoms; 3. refusal to participate in the study; 4. other conditions judged by the investigator to be unsuitable for enrollment.
a clinical trial of oral suberoylanilide hydroxamic acid (saha) in patients with relapsed or refractory breast, colorectal and non-small cell lung cancer (0683-011)(terminated)

Conditions: Breast Cancer; Colorectal Cancer; Non-small-cell Lung Carcinoma

Summary: this is an investigational study to determine the response rate of relapsed/refractory breast, colorectal and non-small cell lung cancer to oral suberoylanilide hydroxamic acid (saha), to evaluate pet as an earlier indicator of response to saha as assessed by response evaluation criteria in solid tumours (recist) criteria and to evaluate the safety and tolerability of oral suberoylanilide hydroxamic acid.


Eligibility criteria:
inclusion criteria: * patient must be 18 years or older with confirmed diagnosis of breast adenocarcinoma, colorectal carcinoma or non-small cell lung cancer * patients must have relapsed or refractory disease following at least one chemotherapeutic treatment regimen. * has a measurable, positron emission tomography (pet) assessable lesion * adequate blood, liver, bone marrow and kidney functions * has not received any chemotherapy for at least 4 weeks prior to entry in this study * agrees to take adequate measures to prevent pregnancy. exclusion criteria: * patient has had prior treatment with histone deacetylase (hdac) inhibitor. * patient has had treatment with investigational agents within the last 30 days. * patient has active infection or had intravenous (iv) antibiotic, antiviral, or antifungal medications within 2 weeks of the start of study drugs. * patient has hiv, hepatitis b or hepatitis c infection. * patient is pregnant or lactating. * patient has allergy to any component of the study drug.